Invesco’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-41,150
| Closed | -$992K | – | 4035 |
|
|
2023
Q1 | $992K | Sell |
41,150
-493,716
| -92% | -$6.2M | ﹤0.01% | 2907 |
|
|
2022
Q4 | $5.65M | Buy |
534,866
+508,393
| +1,920% | +$4.1M | ﹤0.01% | 2183 |
|
|
2022
Q3 | $119K | Buy |
26,473
+3,054
| +13% | +$13.9K | ﹤0.01% | 3806 |
|
|
2022
Q2 | $94K | Sell |
23,419
-203,289
| -90% | -$964K | ﹤0.01% | 3899 |
|
|
2022
Q1 | $1.66M | Buy |
226,708
+205,464
| +967% | +$1.23M | ﹤0.01% | 2857 |
|
|
2021
Q4 | $120K | Sell |
21,244
-3,414
| -14% | -$21.7K | ﹤0.01% | 3878 |
|
|
2021
Q3 | $157K | Buy |
24,658
+2,313
| +10% | +$14.9K | ﹤0.01% | 3862 |
|
|
2021
Q2 | $189K | Buy |
22,345
+7,769
| +53% | +$62.7K | ﹤0.01% | 3802 |
|
|
2021
Q1 | $153K | Sell |
14,576
-327,247
| -96% | -$4.6M | ﹤0.01% | 3710 |
|
|
2020
Q4 | $5.79M | Sell |
341,823
-20,880
| -6% | -$313K | ﹤0.01% | 2105 |
|
|
2020
Q3 | $4.65M | Sell |
362,703
-58,916
| -14% | -$744K | ﹤0.01% | 2043 |
|
|
2020
Q2 | $5.95M | Sell |
421,619
-85,866
| -17% | -$1.08M | ﹤0.01% | 1897 |
|
|
2020
Q1 | $4.67M | Buy |
507,485
+354,523
| +232% | +$4.57M | ﹤0.01% | 1930 |
|
|
2019
Q4 | $2.28M | Buy |
+152,962
| New | +$1.36M | ﹤0.01% | 2593 |
|
Other funds holding PRVB
Invesco's PRVB Position: Q2 2023 in Review
Invesco sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 41,150 shares — an estimated $992K sold.
Invesco first reported a position in PRVB in Q4 2019 and held it in 14 quarters. The position peaked at $5.95M in Q2 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Invesco reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Invesco sold 41,150 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $992K.
- Invesco first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Invesco's Provention Bio, Inc. Common Stock position peaked at $5.95M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.